The role of versican in modulating breast cancer cell self-renewal

Molecular Cancer Research

Volumn 11, Issue 5, 2013, Pages 443-455

  Du, William Weidong ^a,c   Fang, Ling ^a,b   Yang, Xiangling ^a,b   Sheng, Wang ^a,b   Yang, Bing L ^a   Seth, Arun ^a,b   Zhang, Yaou ^d   Yang, Burton B ^a,b   Yee, Albert J ^a,c,e  

^a Sunnybrook Health Sciences Centre   (Canada)

^b Department of Laboratory Medicine and Pathobiology ^*  (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d TSINGHUA UNIVERSITY   (China)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; BETA1 INTEGRIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 1; PROTEIN KINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX2; TRICIRIBINE; VERSICAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL RENEWAL; CELL VIABILITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TRANSFECTION; VERSICANS;

EID: 84877888624     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0461     Document Type: Article

References (48)

1. Hill RP, Perris R. "Destemming" cancer stem cells. J Natl Cancer Inst 2007;99:1435-40.
2. Ponti D, Zaffaroni N, Capelli C, Daidone MG. Breast cancer stem cells: an overview. Eur J Cancer 2006;42:1219-24.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
4. Smalley MJ, Clarke RB. The mammary gland "side population": a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia 2005;10:37-47.
5. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006;312: 3701-10.
6. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-82.
7. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702-12.
8. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
9. Clarke MF. A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 2005;56(Suppl 1):64-8.
10. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003;36 (Suppl 1):59-72.
11. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66: 6063-71.
12. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303: 848-51.
13. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
14. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H, et al. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006;84:77-92.
15. Dours-Zimmermann MT, Zimmermann DR. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 1994;269:32992-8.
16. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005;15:483-94.
17. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, et al. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 2007;9:R47.
18. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002; 8:1054-60.
19. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004;10:2491-8.
20. Delpech B, Girard N, Olivier A, Maingonnat C, van Driessche G, van Beeumen J, et al. The origin of hyaluronectin in human tumors. Int J Cancer 1997;72:942-8.
21. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004;18:754-6.
22. Theocharis AD. Versican in health and disease. Connect Tissue Res 2008;49:230-4.
23. Wu Y, Chen L, Cao L, Sheng W, Yang BB. Overexpression of the Cterminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 2004;117:2227-37.
24. Zheng PS, Vais D, Lapierre D, Liang YY, Lee V, Yang BL, et al. PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 2004;117:5887-95.
25. Wu Y, Zhang Y, Cao L, Chen L, Lee V, Zheng PS, et al. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 2001;276:14178-86.
26. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003;30:3-14.
27. Du WW, Yang BB, Yang BL, Deng Z, Fang L, Shan SW, et al. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFRtherapy. PLoS ONE 2011;6:e26396.
28. Paulus W, Baur I, Dours-Zimmermann MT, Zimmermann DR. Differential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 1996;55:528-33.
29. Zucchi I, Sanzone S, Astigiano S, Pelucchi P, Scotti M, Valsecchi V, et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci U S A 2007;104:10476-81.
30. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17: 1253-70.
31. Welm B, Behbod F, Goodell MA, Rosen JM. Isolation and characterization of functional mammary gland stem cells. Cell Prolif 2003;36 (Suppl 1):17-32.
32. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008;10:1433-43.
33. Zako M, Shinomura T, Kimata K. Alternative splicing of the unique "PLUS" domain of chicken PG-M/versican is developmentally regulated. J Biol Chem 1997;272:9325-31.
34. Sandell LJ. In situ expression of collagen and proteoglycan genes in notochord and during skeletal development and growth. Microsc Res Tech 1994;28:470-82.
35. Yang BL, Cao L, Kiani C, Lee V, Zhang Y, Adams ME, et al. Tandem repeats are involved in G1domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complement-binding protein-like motif. J Biol Chem 2000;275:21255-61.
36. Zhang Y, Cao L, Yang BL, Yang BB. The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 1998;273:21342-51.
37. Yang BL, Yang BB, Erwin M, Ang LC, Finkelstein J, Yee AJ. Versican G3 domain enhances cellular adhesion and proliferation of bovine intervertebral disc cells cultured in vitro. Life Sci 2003;73:3399-413.
38. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, et al. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS ONE 2010;5:e13828.
39. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
40. Prenzel N, Zwick E, Leserer M, Ullrich A. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res 2000;2: 184-90.
41. O'Donovan N, Crown J. EGFR and HER-2 antagonists in breast cancer. Anticancer Res 2007;27:1285-94.
42. Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, et al. Inductive mechanisms limiting response to antiepidermal growth factor receptor therapy. Endocr Relat Cancer 2006;13(Suppl 1):S89-97.
43. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
44. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85.
45. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65: 4320-33.
46. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
47. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
48. Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003;30:12-20.